Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Beat the Market on Monday

By Eric Volkman – Nov 15, 2021 at 5:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported some good news in an important Asian market.

What happened

Novavax (NVAX -6.50%), best known these days for the NVX-CoV2373 coronavirus vaccine it's developed, saw its shares rise by 1.5% on Monday, against a stock market that essentially traded sideways. Investors seemed to be cautiously optimistic about the company's latest news on the regulatory front.

So what

Novavax announced that it has formally submitted a biologics license application (BLA) for NVX-CoV2373 to South Korea's Ministry of Food and Drug Safety. It has done so in collaboration with South Korean biotech SK bioscience.

A person gives an inoculation to a person in the passenger seat of car.

Image source: Getty Images.

That move comes slightly over half a year after Novavax and SK bioscience started the rolling submission process to the Ministry. If the country approves the BLA, it will be a ready customer for the vaccine, as SK bioscience has secured an advance purchase agreement with the government for 40 million doses.

Although NVX-CoV2373 still hasn't been submitted for authorization by the FDA in the crucial U.S. market, it has won nods in various other jurisdictions, for example in Indonesia. It is under review in a clutch of others, including the U.K. and Canada.

Novavax didn't hesitate to point out that the South Korea filing marks a big step forward for NVX-CoV2373. It quoted CEO Stanley Erck as saying that the submission "reflects the first BLA submission for full approval of our COVID-19 vaccine anywhere in the world, with more anticipated to follow."

Now what

The news was tempered by the hard fact that Novavax would be far from a first mover in South Korea. All three vaccines either approved or authorized for emergency use in the U.S. -- Moderna's mRNA-1273 (aka Spikevax), Pfizer and BioNTech's Comirnaty, and the single-dose vaccine from Johnson & Johnson -- all have that status. AstraZeneca and Oxford University's AZD1222 has also won approval.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson and Moderna Inc. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.